TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01137357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt with L. plantarum strain
Description: Intake of yoghurt during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yoghurt with L.casei
Description: Intake of yoghurt during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt with L. plantarum strain
Description: Intake of yoghurt during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt with L. plantarum strain
Description: Yoghurt with L. plantarum strain

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt with L. plantarum strain
Description: Intake of yoghurt during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt
Description: Intake of yoghurt during 4 weeks
Study: NCT01804738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parboiled basmati rice
Description: Standardised rice:cooking liquid for 50g available carbohydrate portion
Study: NCT04499313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Injectable solution
Study: NCT00378326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
Study: NCT01450462

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
Study: NCT01582126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group balance training
Description: Balance training i group with focus on core stability exercises and dual attention activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group balance training
Description: Balance training i group with focus on core stability exercises and dual attention activities.
Study: NCT04140188

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Senti-Scint (99mTc- pertechnetate combined with human albumin)
Description: Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Senti-Scint (99mTc- pertechnetate combined with human albumin)
Description: Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
Study: NCT03472365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
Study: NCT02688348

Intervention type: OTHER
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03472365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
Study: NCT03769844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
Study: NCT03657329

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dreem
Description: Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
Study: NCT00902109

Intervention type: DEVICE
Intervention: Perimetry
Description: different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold

Intervention type: DEVICE
Intervention: Confocal Scanning Laser Tomography
Description: HRT examinations for the clinical evaluation of the optic disc.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: imaging of the retinal nerve fiber layer
Study: NCT03025880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
Study: NCT04259528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric endoscopic ultrasound
Description: endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
Study: NCT01487369

Intervention type: DRUG
Intervention: insulin aspart
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
Study: NCT02377895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasapaque Nasal Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Saline Nasal Solution
Study: NCT02648620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurVeil Drug Coated Balloon
Description: Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
Study: NCT03127904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein Fitness
Description: Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compressive therapy and wound care
Description: Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compressive therapy and wound care
Description: Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it.
Study: NCT04067102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Description: Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Description: Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
Study: NCT04499313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Injectable solution
Study: NCT01217307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg twice daily during 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily during 4 months
Study: NCT02353169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Study: NCT00436553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin Photodynamic Therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg administered as an intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg administered as an intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg administered as an intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Placebo
Description: To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Placebo
Description: To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Placebo
Description: To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
Study: NCT01826383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active-Video
Description: This group will watch an active-video with pain management strategies for parents

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Video
Description: This group will watch a placebo-video describing immunization generally.
Study: NCT01488630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STaRS
Description: The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
Study: NCT02175706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity®
Description: Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element®
Description: fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
Study: NCT02609464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted Knotted Sutures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices
Study: NCT04829227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study: NCT03194412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet /nutritional
Description: • Duration:~* the first stage - 3 months: 12 weeks~* second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~* make a diet modification to include the products recommended in frailty~* modifying eating habits~The diet modification is mainly focused on adequate supply:~* vitamin D (according to Central Europe guidelines -2013 for seniors)~* protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: * Duration:~  * the first stage - 3 months: 12 weeks~ * second stage - 3 months: 12 weeks~* Frequency: twice a week~* Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~* resistance exercises and strength training, which aim to improve muscle strength in the limbs~* exercises aimed at improving motor coordination, flexibility and speed~* stretching exercises.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy
Description: Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~* the first stage - 3 months- 12 weeks~* the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregivers of elderly
Description: Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~* the first stage - 3 months: 12 weeks~* the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes
Study: NCT01522664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEDN6526A
Description: Multiple ascending doses
Study: NCT00877032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN6G
Description: intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous, single dose with experimental dose.
Study: NCT01823965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study: NCT01122485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG201
Description: two tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG201
Description: two tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets
Study: NCT01269801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: * Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JUVÉDERM
Description: Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Study: NCT01453556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
Study: NCT02726230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ananya
Description: The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
Study: NCT01205295

Intervention type: OTHER
Intervention: Cognitive behavioural therapy
Description: Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
Study: NCT01283932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg
Study: NCT00888511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Tarceva 150 mg/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 66 Gy/33 F/5 F per week for 5 weeks
Study: NCT01561651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion
Description: Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
Study: NCT00434525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic restrictive procedure
Description: Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy
Study: NCT00217919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-Counselor Mediated Telephone Counseling Intervention
Description: A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity.